Spotlight on drug pricing could be catalyst for change in US biosimilar landscape

Spotlight on drug pricing could be catalyst for change in US biosimilar landscape

Source: 
Endpoints
snippet: 

While biosimilar makers have long established themselves in Europe, only a few copycat versions of biologics have launched in the nascent US market, which is beginning to show signs of maturing, but is complicated by a reimbursement landscape fractured by multiple players. The spotlight on drug pricing, however, may at long last provide the catalyst for change.